

# Quanterix™

## Quanterix to Present at 40th Annual J.P. Morgan Healthcare Conference

January 6, 2022

BILLERICA, Mass.--(BUSINESS WIRE)--Jan. 6, 2022-- [Quanterix Corporation](#) (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chairman and Chief Executive Officer, and Founder of [Powering Precision Health](#) (PPH), Kevin Hrusovsky, will be presenting on the Company's growth and vision for the sixth consecutive year at the 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference. Hrusovsky's session will take place on Thursday, Jan. 13, 2022, at 8:15 a.m., EST (5:15 a.m., PST) and will be made available to attendees and the general public. In addition to Hrusovsky's session, he will also be hosting one-on-one meetings with institutional investors during the conference.

### Webcast Information

To access the live webcast of Quanterix' presentation at the 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 13, 2022 at 8:15 a.m., EST (5:15 a.m., PST), please visit: [https://jpmorgan.metameetings.net/events/healthcare22/sessions/39930-quanterix-corporation/webcast?gpu\\_only=true&kiosk=true](https://jpmorgan.metameetings.net/events/healthcare22/sessions/39930-quanterix-corporation/webcast?gpu_only=true&kiosk=true)

Replays of the webcasts will be available for a limited period following the conference.

### About Quanterix

Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit <https://www.quanterix.com>.

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220106005661/en/): <https://www.businesswire.com/news/home/20220106005661/en/>

### Media:

PAN Communications  
Paige Romine, (321) 652-8370  
[pan.quanterix@pancomm.com](mailto:pan.quanterix@pancomm.com)

### Investor Relations:

Stephen Hrusovsky  
(774) 278-0496  
[shrusovsky@quanterix.com](mailto:shrusovsky@quanterix.com)

Source: Quanterix Corporation